Wealthfront Advisers’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
Wealthfront Advisers's MRNA Position: Q3 2026 in Review
Wealthfront Advisers increased its Moderna (MRNA) stake by 413% in Q3 2026, buying an estimated $6.95M and bringing the position to 80,105 shares worth $15.4M. The position accounts for 0.03% of the portfolio, ranked #198.
Wealthfront Advisers first reported a position in MRNA in Q2 2021 and has held it in 20 quarters since. 1,048 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.
- Wealthfront Advisers held 80,105 shares of Moderna worth $15.4M as of Q3 2026.
- Wealthfront Advisers bought 64,484 Moderna shares in Q3 2026, an estimated $6.95M.
- Moderna made up 0.03% of Wealthfront Advisers's portfolio in Q3 2026, its #198 holding.
- Wealthfront Advisers first reported a position in Moderna in Q2 2021 and has held it in 20 quarters since.
- 1,048 funds tracked by Wall St. Rank held Moderna as of Q3 2026.
Based on Wealthfront Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.